

# Partnering Activity Update

**November 1, 2023**

# Cautionary Notes

***Forecasts and other forward-looking statements included in this document are based on information currently available and certain assumptions that the Company deems reasonable.***

***Actual performance and other results may differ significantly due to various factors. Such factors include, but are not limited to:***


- ( i ) failures in new product development***
- ( ii ) changes in general economic conditions due to reform of medical insurance system***
- ( iii ) failures in obtaining the expected results due to effects of competing products or generic drugs***
- ( iv ) infringements of the Company's intellectual property rights by third parties***
- ( v ) stagnation of product supply from the delay in production due to natural disasters, fires and so on***
- ( vi ) onset of new side effect of post-licensure medical product***
- and, ( vii ) currency exchange rate fluctuations and interest rate trend.***

***Information about pharmaceutical products (including products currently in development) included in this document is not intended to constitute an advertisement of medical advice.***

# Collaboration with BMS for OPDIVO®

Start collaboration  
in May 2005


Expand collaboration  
in Sep 2011




# Strategic Alliance with BMS in JP, KR & TW

- To Strengthen Immuno-oncology Portfolio
- To Accelerate Combination Therapies

## Co-development




## Co-promotion




Development cost share

Profit/loss allocation



# Collaboration with BMS for ORENCIA®

- Biologic Inhibiting Upstream Inflammation in RA





**ONO PHARMACEUTICAL CO.,LTD.**

*Dedicated to the Fight against Disease and Pain*